MetaCap

Acumen Pharmaceuticals (ABOS) vs Estrella Immunopharma (ESLA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Estrella Immunopharma (ESLA) has outperformed Acumen Pharmaceuticals (ABOS) over the past year, losing 78.9% versus a loss of 88.1%. Over five years, ESLA leads with a -96.8% price change compared with -97.7% for ABOS. Estrella Immunopharma is the larger company by market cap ($14.1 million vs $13.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABOS-88.12%ESLA-78.88%
+125%+13%-98%
Nov 21, 20251 yearNov 20, 2026
ABOS-98.11%ESLA-96.76%
+125%+8%-109%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABOS versus ESLA key metrics
MetricABOSESLA
Share price$0.1865$0.321
Market cap$13.49M$14.11M
1-day change-3.52%-5.70%
YTD return-91.16%-79.42%
1-year return-88.12%-78.88%
5-year return-97.74%-96.78%
EPS (TTM)$-1.55$-0.29
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-121.33M$-13.06M
52-week high$3.60$2.27
52-week low$0.16$0.24
Distance from 52-week high-94.82%-85.86%
Analyst consensusstrong_buynone
Avg. price target upside+3975.07%+3638.32%
Average volume2.73M2.04M
Shares outstanding72.33M43.97M
Employees60—
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Acumen Pharmaceuticals

ABOS stock →

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees

About Estrella Immunopharma

ESLA stock →

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances)

ABOS vs ESLA FAQ

Which is bigger, Acumen Pharmaceuticals or Estrella Immunopharma?

Estrella Immunopharma (ESLA) is larger, with a market capitalization of $14.11M compared with $13.49M for Acumen Pharmaceuticals (ABOS).

Which stock has performed better over the past year, ABOS or ESLA?

ESLA returned -78.88% over the past 12 months, compared with -88.12% for ABOS (price return, excluding dividends). Past performance does not predict future results.

Are Acumen Pharmaceuticals and Estrella Immunopharma in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons